JessicaH_TX said:Orforglipron is the more interesting oral story because it is not a peptide at all.
I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.
Adding the numbers, since they settle part of this. One habit that pays for itself: post the method alongside the number. A figure without its method cannot be checked, and an unchecked figure is how this community accumulates folklore.
Dr.GastroMayo said:I do not accept that the fasting window is a minor inconvenience.
Coming at Dr.GastroMayo’s question from a different direction. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.
That is the short version; the long version is somebody else's post.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsA narrower follow-up, since the general answer is now clear:
How much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly?
Reporting back.
I moved the tablet to the moment I wake up rather than trying to fit it around breakfast, and the difference in the following weeks was obvious. It was a timing problem, not a dose problem.